Xaira Therapeutics vs GE HealthCare

Side-by-side comparison of AI visibility scores, market position, and capabilities

GE HealthCare leads in AI visibility (93 vs 59)
Xaira Therapeutics logo

Xaira Therapeutics

ChallengerHealthcare & Life Sciences

AI Drug Discovery

AI drug discovery startup launched with $1B funding. Led by ex-Stanford president + Nobel laureate David Baker. Focus: inflammatory/immunological diseases. Founded 2024, South SF.

AI VisibilityBeta
Overall Score
C59
Category Rank
#3 of 7
AI Consensus
55%
Trend
up
Per Platform
ChatGPT
50
Perplexity
68
Gemini
61

About

Xaira Therapeutics is an AI-powered drug discovery company launched from stealth in April 2024 with $1 billion in committed capital. Headquartered in South San Francisco, incubated by Arch Venture Partners and Foresite Capital. Led by CEO Marc Tessier-Lavigne (ex-Stanford president, ex-Genentech CSO) and co-founder David Baker (Nobel laureate, UW Institute for Protein Design).

Full profile
GE HealthCare logo

GE HealthCare

LeaderHealthcare Tech

Enterprise

Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.

AI VisibilityBeta
Overall Score
A93
Category Rank
#183 of 290
AI Consensus
61%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
95
Gemini
85

About

GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.

Full profile

AI Visibility Head-to-Head

59
Overall Score
93
#3
Category Rank
#183
55
AI Consensus
61
up
Trend
stable
50
ChatGPT
99
68
Perplexity
95
61
Gemini
85
54
Claude
84
52
Grok
89

Key Details

Category
AI Drug Discovery
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Xaira Therapeutics
AI Drug Discovery
GE HealthCare is classified as company (part of GE Aerospace).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.